Early Clinical Validation of GF-CART01: A Non-Viral Dual-Targeting CAR-T Therapy for Relapsed/Refractory B-Cell Malignancies
- Introducing Quantum Engine for non-viral gene therapy
- Describing the benefits of dual-targeting CD19/CD20 T(SCM) cells to overcome antigen escape and improve response durability
- Presenting preliminary findings from a Phase I open-label trial of GF-CART01 for relapsed or refractory B-cell hematologic cancers